Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
独立董事关于控股股东及其他关联方占用公司资金、对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's related party fund occupation and external guarantees for the fiscal year 2022. It references regulatory notices from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines. The content is focused on compliance and independent verification rather than presenting full financial data or audit results. The document length is short (632 characters) and it is a formal opinion statement rather than a full audit report or annual report. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal or regulatory compliance, excluding full annual reports. FY 2022
2023-04-21 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 First Quarter Report" of Enwei Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2023. The document explicitly states it is a quarterly report and mentions it is unaudited. The length of the document (over 10,000 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-21 Chinese
关于续聘2023年度财务审计机构的公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the reappointment of the company's financial audit firm for the year 2023. It details the audit firm's qualifications, independence, audit fees, and the approval process by the board, audit committee, supervisory board, and independent directors. There is no actual audit report or financial statements included, only information about the appointment of the audit firm and related procedural approvals. The document length is 3349 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates specifically to audit firm appointment and audit-related information, but is not a full annual report or audit report itself. However, given the short length and nature of the document, it could also be considered a Regulatory Filing (RNS) as a fallback. But since it is specifically about audit firm appointment and audit-related information, AR is the most appropriate classification. FY 2023
2023-04-21 Chinese
2022年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the annual deposit and use of raised funds for the year 2022 by Enwei Pharmaceutical Co., Ltd. It details the amount of funds raised, their allocation, usage, storage, and management, including audit and verification reports by accounting firms and securities companies. The document references regulatory guidelines related to the management and use of raised funds and includes detailed financial figures and tables about the fundraising and usage. This is a specialized report focused on the use of capital raised by the company, not a general annual report or earnings release. It fits the category of Capital/Financing Update (CAP) as it provides updates on fundraising and capital usage activities.
2023-04-21 Chinese
关于 2023 年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected amount of daily related party transactions for the year 2023 by 恩威医药股份有限公司. It includes details about the related party, transaction amounts, pricing principles, and opinions from independent directors and the supervisory board. The document is a formal disclosure of anticipated related party transactions, which is a regulatory announcement to inform shareholders and the market. It does not contain financial statements, audit results, or detailed financial performance data. The document length is 3736 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-21 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2022年度募集资金存放与使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2022 annual special verification opinion on the storage and use of raised funds by Enwei Pharmaceutical Co., Ltd. It includes specifics on the amount of funds raised, their allocation, usage, management, and compliance with regulatory requirements. It also contains an auditor's verification opinion and the sponsor's main verification work and conclusion. The document references regulatory guidelines related to fundraising and fund management, and it is a comprehensive report on the use of capital raised through an IPO. This matches the characteristics of a Capital/Financing Update (CAP) filing, as it focuses on fundraising and the use of proceeds rather than a full annual report or audit report. The document length is substantial and contains detailed financial and compliance information about the capital raised and its usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-04-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.